ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

RGLS Regulus Therapeutics Inc

2,69
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 13:28:32
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Regulus Therapeutics Inc RGLS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 2,69 13:28:32
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,69
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202414:00PRNUSRegulus Therapeutics to Participate in the Canaccord Genuity..
21.3.202421:05PRNUSRegulus Therapeutics Reports Fourth Quarter and Year-End..
12.3.202411:32PRNUSRegulus Therapeutics Announces Oversubscribed $100 Million..
12.3.202411:30PRNUSRegulus Therapeutics Announces Positive Topline Data from..
19.1.202402:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202422:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
10.1.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02.1.202422:05PRNUSRegulus Therapeutics Announces Completion of Enrollment in..
27.12.202322:16EDGAR2Form S-3 - Registration statement under Securities Act of..
22.11.202314:00PRNUSRegulus Therapeutics to Present at the 6th Annual Evercore..
09.11.202322:39EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202322:15EDGAR2Form 8-K - Current report
09.11.202322:05PRNUSRegulus Therapeutics Reports Third Quarter 2023 Financial..
02.11.202313:00PRNUSRegulus Therapeutics Announces First Patient Dosed in Third..
19.10.202314:00PRNUSRegulus Therapeutics Advances to Cohort 3 of Phase 1b..
20.9.202313:00PRNUSRegulus Therapeutics Announces Positive Topline Data from..
13.9.202314:00PRNUSRegulus Therapeutics Announces Completion of Enrollment in..
05.9.202314:00PRNUSRegulus Therapeutics Announces Participation at Two..
23.8.202314:00PRNUSRegulus Therapeutics to Host Virtual Investor Event on..
14.8.202322:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.8.202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202322:15EDGAR2Form 8-K - Current report
08.8.202322:05PRNUSRegulus Therapeutics Reports Second Quarter 2023 Financial..
02.8.202314:00PRNUSRegulus Therapeutics to Present at the Canaccord Genuity..
18.7.202314:00PRNUSRegulus Therapeutics to Present at the H.C. Wainwright 2nd..
29.6.202322:53EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.6.202314:00PRNUSRegulus Therapeutics Announces First Patient Dosed in Second..
23.6.202314:00PRNUSRegulus Therapeutics Announces Appointment of Preston S...
20.6.202314:00PRNUSRegulus Therapeutics Announces Update on Preclinical Studies..
12.6.202314:00PRNUSRegulus Therapeutics Strengthens Research & Development..
16.5.202314:00PRNUSRegulus Therapeutics Advances to Cohort 2 of Phase 1b..
11.5.202322:05PRNUSRegulus Therapeutics Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock